TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline in Van Der Heijde Total Modified Total Sharp Score (mTSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Pre-treatment in Normalized Radiographic Progression of mTSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area Under the Concentration-time Curve of Spesolimap in Plasma (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of Spesolimap in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of diabetic retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Change in the Clinician-Administered PTSD Scale (CAPS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum concentration (tmax) of JNJ-63623872
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Last (AUC [0-last]) of JNJ-63623872
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Rapid Viral Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with ALT elevations (> 10 x ULN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of participants with any on-treatment adverse event (AE) or serious adverse event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in white blood cell count (WBC) and other blood cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in hemoglobin and mean corpuscle hemoglobin concentration (MCHC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in visual cutaneous symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of children with stable anxiety scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of LUS in diagnosing heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reproducibility of LUS in diagnosing heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tissue biomarkers of prostate cancer susceptibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fractional Synthetic Rate (Muscle Protein Synthesis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cross-sectional area of paraspinal muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Performance time of paraspinal muscle endurance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Weekly mean of the daily bloating scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Presence of atrial fibrillation symptoms and their impact on quality of life using the Severity of Atrial Fibrillation (SAF) scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cortical brain activation pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Alcohol Use Disorder Identification -C (AUDIT-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum neuron-specific enolase (NSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: S100B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Carotid occlusion intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day postoperative comorbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity to HPV Vaccine Gardasil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Trocar slippage incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline Symptoms of Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Symptoms of Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Symptoms of Post Traumatic Stress Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Overactive Bladder Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concordance on the IPS value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Cmax (maximum concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Tmax (Time of maximum concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics AUC (Area Under the Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nebulization success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sway index of sensory integration test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DLCo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Past Week Nightmare Frequency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Inflammatory index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximal amplitude of the tracheal tube shifting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent of Participants With Biopsy-Proven Acute and/or Chronic Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of Participants With Grade 3 or Higher Infectious Adverse Event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Participants With Grade 3 or Higher Wound Complication(s) Adverse Event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Participants With Grade 2 or Higher Hematologic Adverse Events (AEs) of Anemia, Neutropenia, and/or Thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Retinal capillary density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nail fold capillary numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Evidence of ulcerative colitis, Crohn's disease or indeterminate colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of Correlation of Ventilation Images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Experiencing Major or Clinically Relevant Non-major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Overall clinical benefit rate (CBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Monocular Logarithm of the Minimum Angle of Resolution (logMAR) Visual Acuity - Standard High Contrast Dim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular logMar Visual Acuity - Standard Low Contrast Bright
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Retention Over Time
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Depression symptoms (PHQ-8 questionnaire) Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Depression symptoms (CES-D questionnaire) Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Serum HGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of cases with confirmed preoperative diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined endpoint of strategy success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary artery calcification (CAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Target Lesion Severity (TLS) Score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage time-in-range of interstitial glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage time in hypoglycemia of interstitial glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage time in severe hyperglycemia of interstitial glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Interleukin 5 Serum Cytokine Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin 10 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin 17A Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interferon Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence rate of all-cause mortality at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rate of stroke at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rate of all-cause mortality at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rate of stroke at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Cancer pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength and muscle tension grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quality of Life Score of Tumor Patients(0-60)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Days of hospitalization after surgery until discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Score based on the Clavien-Dindo classification system
Endpoint domain: Adverse events/effects
Primary endpoint: Mean pain during brachytherapy applicator installations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound drainage time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiographical assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capacity of dendritic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum HCV Viral Load (VL) Change From Baseline Over Time Following Single-Dose MK-1075
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With at Least 50 Percent Reduction in PASI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Participants With Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Successful completion of 2 injections without dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced at Least One Treatment Related Grade 3-5 AE
Endpoint domain: Adverse events/effects
Primary endpoint: Clearance of 13C-RG1662
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of 13C-RG1662
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mullen Scales of Early Learning - Early Learning Composite
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Knee Society Knee Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent reduction in 24 hour urine protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Psychotic Symptom Rating Scale - auditory hallucinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with route of administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in defecation consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of encopresis/soiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tmax (The Time to Maximum Observed Plasma Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast (the Area Under the Plasma Concentration-time Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASIA scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with CTV not covered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Joint Chemical Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burden of illness due to herpes zoster
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvement in net protein muscle balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overnight Urinary Cortisol creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Decrease in PANSS negative subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Response (Complete and Partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in American Shoulder and Elbow Surgeons Score (ASES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of the training of PCPs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Correlation coefficient between mean vacuole areas in sperm heads and sperm aneuploidy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Patient satisfaction with breast surgeon
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nasal and ocular symptoms scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cystic Fibrosis Knowledge Questionnaire (CFK)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Depression, Anxiety and Stress Scale - 21 (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With ACR20 Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Balance stability margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Bruininks-Osteretsky Test of Motor Proficiency, Second Edition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with vaginal stump infection
Endpoint domain: Adverse events/effects
Primary endpoint: Opioid related adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Understanding of mild cognitive impairment as a potential precursor to dementia--knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Understanding of mild cognitive impairment as a potential precursor to dementia-Coherence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perceived efficacy to cope with mild cognitive impairment as a potential precursor to dementia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal reflective capacities
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Infant Attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal life course outcomes
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Child abuse or neglect
Endpoint domain: Adverse events/effects
Primary endpoint: Vancomycin exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall cosmetic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of microscopic colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Compliance to secondary prevention treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MS-specific peripheral blood gene expression patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in peripheral blood gene expression patterns between subgroups of MS patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MS-specific peripheral blood inflammatory marker profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Asthma exacerbation rate ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hypoglycemic and Hyperglycemic Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Collagen Synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of effective contraception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hSPCA1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of veins with durable isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change score of low density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression-Free Survival Rate (PFS Rate)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Pharyngeal residue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: premature infant pain profile (PIPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Receiver Operating Curve (ROC AUC) Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TKI resistance gene mutation pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermic effect of meals (TEM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the Severity of Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in functional level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically definite urinary tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serious incidents on ward
Endpoint domain: Adverse events/effects
Primary endpoint: Pregnancy viability
Endpoint domain: Mortality/survival
Primary endpoint: Circumferential Chest Size Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with an adverse event related to the treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative number of MRI T2 lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Tolerance of the Certican®-Envarsus® association
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of lymphocytes, myeloid and mesenchymal populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incident and persistent HPV infection at one-year follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence, persistence and progression of histopathologic abnormality at one-year follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Device related safety issues
Endpoint domain: Adverse events/effects
Primary endpoint: SOLO use errors
Endpoint domain: Adverse events/effects
Primary endpoint: Device-related adverse outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Knee Joint Biomechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metastatic lymph node status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical efficacy of Favipiravir in treating influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Blood markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Forced Exhaled Volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in phenotyping measures of probe drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microcomedone Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Stress measured by the Cohen Perceived Stress Scale (PSS-10)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status